Advanced Search
Contact | Corporate | Help

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Lysosomal Acid Lipase Deficiency

Sponsors:
  • Synageva BioPharma Corp.
Phases:
  • Phase II
IndicationsAcronym:
  • Cholesterol Ester Storage Disease(CESD)
  • Lysosomal Acid Lipase Deficiency
Age Groups:
  • Adult
Gender:
Both
Names:
  • Drug: SBC-102
  • Drug: SBC-102
  • Drug: SBC-102
Enrollment:
9

Additional information about NCT01488097.


SourceSolution © 2008-2012